European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union

Parexel collaborates with Japanese Foundation for cancer research

Collaboration streamlines patient access to oncology clinical trials

Nucala approved in China for use in severe asthma with an eosinophilic phenotype

Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data

USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy

CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China

Innovent will supply sintilimab for the collaborated clinical trial

Pigeon Singapore, LyondellBasell collaborate to incorporate bio-circular plastic in nursing bottles

The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes

Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment

US FDA approval based on NEURO-TTRansform Phase III results

BioVaxys executes LoI for major Immunotherapeutics technology acquisition

BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement